Neurogenic Orthostatic Hypotension Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Type (Midodrine, Fludrocortisone, Yohimbine, Droxidopa, Atomoxetine); Non- Pharmacological treatment options (Lifestyle changes, Hydration, Leg Crossing, Reducing Medications); End User (Hospitals, Diagnostic centers, Clinics, Ambulatory surgical centers) and Geography

Report Code: TIPRE00018834 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Neurogenic Orthostatic Hypotension is a situation in which the autonomic system which controls all the automatic function of body fails to function properly which ultimately results into sudden and dangerous drop in blood pressure. The neurogenic orthostatic hypotension gives drop in blood pressure even if patient sits, changes position or lay down on bed. The symptoms of this condition are, cognitive impairment, difficulty in breathing, fatigue, blurred vision.

MARKET DYNAMICS

The key market drivers for Neurogenic Orthostatic Hypotension Market Includes, rising incidences of cardiovascular disorders such as hypertension, growing ageing population across the globe along with availability of novel treatment options. However, side effects associated with the treatment is expected to restrain market growth.

MARKET SCOPE

The "Neurogenic Orthostatic Hypotension Market" is a specialized and in-depth study of the Pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Neurogenic Orthostatic Hypotension market with detailed market segmentation by drug type, non- pharmacological treatment options, and end user. The Neurogenic Orthostatic Hypotension Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Neurogenic Orthostatic Hypotension Market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Neurogenic Orthostatic Hypotension Market is segmented on the basis of drug type, non- pharmacological treatment options, and end user. On the basis of drug type the market is segmented as, midodrine, fludrocortisone, yohimbine, droxidopa, atomoxetine. On the basis of non- pharmacological treatment option the market is segmented as, lifestyle changes, hydration, leg crossing, reducing medications. And on the basis of end user the market is segmented as, hospitals, diagnostic centers, clinics, ambulatory surgery centers.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Neurogenic Orthostatic Hypotension Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Neurogenic Orthostatic Hypotension Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Neurogenic Orthostatic Hypotension Market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Neurogenic Orthostatic Hypotension Market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Neurogenic Orthostatic Hypotension Markets organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Neurogenic Orthostatic Hypotension Market are anticipated to have lucrative growth opportunities in the future with the rising demand for, Neurogenic Orthostatic Hypotension market in the global market. Below mentioned is the list of few companies engaged in the Neurogenic Orthostatic Hypotension Market.

The report also includes the profiles of key players in Neurogenic Orthostatic Hypotension Market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered financial information of last 3 years, key development in past five years.
- Amgen
- Upsher-Smith Laboratories
- Mylan, Inc.
- Chelsea Therapeutics
- Apotex, Inc.
- Amneal Pharmaceuticals, Inc.
- H. Lundbeck AS
- F. Hoffmann La Roche
- Novartis AG
- Pfizer, Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Neurogenic Orthostatic Hypotension Market - By Drug Type
1.3.2 Neurogenic Orthostatic Hypotension Market - By Non- Pharmacological treatment options
1.3.3 Neurogenic Orthostatic Hypotension Market - By End User
1.3.4 Neurogenic Orthostatic Hypotension Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. NEUROGENIC ORTHOSTATIC HYPOTENSION MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. NEUROGENIC ORTHOSTATIC HYPOTENSION MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. NEUROGENIC ORTHOSTATIC HYPOTENSION MARKET - GLOBAL MARKET ANALYSIS
6.1. NEUROGENIC ORTHOSTATIC HYPOTENSION - GLOBAL MARKET OVERVIEW
6.2. NEUROGENIC ORTHOSTATIC HYPOTENSION - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. NEUROGENIC ORTHOSTATIC HYPOTENSION MARKET - REVENUE AND FORECASTS TO 2028 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. MIDODRINE
7.3.1. Overview
7.3.2. Midodrine Market Forecast and Analysis
7.4. FLUDROCORTISONE
7.4.1. Overview
7.4.2. Fludrocortisone Market Forecast and Analysis
7.5. YOHIMBINE
7.5.1. Overview
7.5.2. Yohimbine Market Forecast and Analysis
7.6. DROXIDOPA
7.6.1. Overview
7.6.2. Droxidopa Market Forecast and Analysis
7.7. ATOMOXETINE
7.7.1. Overview
7.7.2. Atomoxetine Market Forecast and Analysis
8. NEUROGENIC ORTHOSTATIC HYPOTENSION MARKET - REVENUE AND FORECASTS TO 2028 - NON- PHARMACOLOGICAL TREATMENT OPTIONS
8.1. OVERVIEW
8.2. NON- PHARMACOLOGICAL TREATMENT OPTIONS MARKET FORECASTS AND ANALYSIS
8.3. LIFESTYLE CHANGES
8.3.1. Overview
8.3.2. Lifestyle changes Market Forecast and Analysis
8.4. HYDRATION
8.4.1. Overview
8.4.2. Hydration Market Forecast and Analysis
8.5. LEG CROSSING
8.5.1. Overview
8.5.2. Leg Crossing Market Forecast and Analysis
8.6. REDUCING MEDICATIONS
8.6.1. Overview
8.6.2. Reducing Medications Market Forecast and Analysis
9. NEUROGENIC ORTHOSTATIC HYPOTENSION MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. DIAGNOSTIC CENTERS
9.4.1. Overview
9.4.2. Diagnostic centers Market Forecast and Analysis
9.5. CLINICS
9.5.1. Overview
9.5.2. Clinics Market Forecast and Analysis
9.6. AMBULATORY SURGICAL CENTERS
9.6.1. Overview
9.6.2. Ambulatory surgical centers Market Forecast and Analysis

10. NEUROGENIC ORTHOSTATIC HYPOTENSION MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Neurogenic Orthostatic Hypotension Market Overview
10.1.2 North America Neurogenic Orthostatic Hypotension Market Forecasts and Analysis
10.1.3 North America Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Drug Type
10.1.4 North America Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Non- Pharmacological treatment options
10.1.5 North America Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By End User
10.1.6 North America Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Countries
10.1.6.1 United States Neurogenic Orthostatic Hypotension Market
10.1.6.1.1 United States Neurogenic Orthostatic Hypotension Market by Drug Type
10.1.6.1.2 United States Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.1.6.1.3 United States Neurogenic Orthostatic Hypotension Market by End User
10.1.6.2 Canada Neurogenic Orthostatic Hypotension Market
10.1.6.2.1 Canada Neurogenic Orthostatic Hypotension Market by Drug Type
10.1.6.2.2 Canada Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.1.6.2.3 Canada Neurogenic Orthostatic Hypotension Market by End User
10.1.6.3 Mexico Neurogenic Orthostatic Hypotension Market
10.1.6.3.1 Mexico Neurogenic Orthostatic Hypotension Market by Drug Type
10.1.6.3.2 Mexico Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.1.6.3.3 Mexico Neurogenic Orthostatic Hypotension Market by End User
10.2. EUROPE
10.2.1 Europe Neurogenic Orthostatic Hypotension Market Overview
10.2.2 Europe Neurogenic Orthostatic Hypotension Market Forecasts and Analysis
10.2.3 Europe Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Drug Type
10.2.4 Europe Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Non- Pharmacological treatment options
10.2.5 Europe Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By End User
10.2.6 Europe Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Neurogenic Orthostatic Hypotension Market
10.2.6.1.1 Germany Neurogenic Orthostatic Hypotension Market by Drug Type
10.2.6.1.2 Germany Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.2.6.1.3 Germany Neurogenic Orthostatic Hypotension Market by End User
10.2.6.2 France Neurogenic Orthostatic Hypotension Market
10.2.6.2.1 France Neurogenic Orthostatic Hypotension Market by Drug Type
10.2.6.2.2 France Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.2.6.2.3 France Neurogenic Orthostatic Hypotension Market by End User
10.2.6.3 Italy Neurogenic Orthostatic Hypotension Market
10.2.6.3.1 Italy Neurogenic Orthostatic Hypotension Market by Drug Type
10.2.6.3.2 Italy Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.2.6.3.3 Italy Neurogenic Orthostatic Hypotension Market by End User
10.2.6.4 Spain Neurogenic Orthostatic Hypotension Market
10.2.6.4.1 Spain Neurogenic Orthostatic Hypotension Market by Drug Type
10.2.6.4.2 Spain Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.2.6.4.3 Spain Neurogenic Orthostatic Hypotension Market by End User
10.2.6.5 United Kingdom Neurogenic Orthostatic Hypotension Market
10.2.6.5.1 United Kingdom Neurogenic Orthostatic Hypotension Market by Drug Type
10.2.6.5.2 United Kingdom Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.2.6.5.3 United Kingdom Neurogenic Orthostatic Hypotension Market by End User
10.2.6.6 Rest of Europe Neurogenic Orthostatic Hypotension Market
10.2.6.6.1 Rest of Europe Neurogenic Orthostatic Hypotension Market by Drug Type
10.2.6.6.2 Rest of Europe Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.2.6.6.3 Rest of Europe Neurogenic Orthostatic Hypotension Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Neurogenic Orthostatic Hypotension Market Overview
10.3.2 Asia-Pacific Neurogenic Orthostatic Hypotension Market Forecasts and Analysis
10.3.3 Asia-Pacific Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Drug Type
10.3.4 Asia-Pacific Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Non- Pharmacological treatment options
10.3.5 Asia-Pacific Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Neurogenic Orthostatic Hypotension Market
10.3.6.1.1 Australia Neurogenic Orthostatic Hypotension Market by Drug Type
10.3.6.1.2 Australia Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.3.6.1.3 Australia Neurogenic Orthostatic Hypotension Market by End User
10.3.6.2 China Neurogenic Orthostatic Hypotension Market
10.3.6.2.1 China Neurogenic Orthostatic Hypotension Market by Drug Type
10.3.6.2.2 China Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.3.6.2.3 China Neurogenic Orthostatic Hypotension Market by End User
10.3.6.3 India Neurogenic Orthostatic Hypotension Market
10.3.6.3.1 India Neurogenic Orthostatic Hypotension Market by Drug Type
10.3.6.3.2 India Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.3.6.3.3 India Neurogenic Orthostatic Hypotension Market by End User
10.3.6.4 Japan Neurogenic Orthostatic Hypotension Market
10.3.6.4.1 Japan Neurogenic Orthostatic Hypotension Market by Drug Type
10.3.6.4.2 Japan Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.3.6.4.3 Japan Neurogenic Orthostatic Hypotension Market by End User
10.3.6.5 South Korea Neurogenic Orthostatic Hypotension Market
10.3.6.5.1 South Korea Neurogenic Orthostatic Hypotension Market by Drug Type
10.3.6.5.2 South Korea Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.3.6.5.3 South Korea Neurogenic Orthostatic Hypotension Market by End User
10.3.6.6 Rest of Asia-Pacific Neurogenic Orthostatic Hypotension Market
10.3.6.6.1 Rest of Asia-Pacific Neurogenic Orthostatic Hypotension Market by Drug Type
10.3.6.6.2 Rest of Asia-Pacific Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.3.6.6.3 Rest of Asia-Pacific Neurogenic Orthostatic Hypotension Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Neurogenic Orthostatic Hypotension Market Overview
10.4.2 Middle East and Africa Neurogenic Orthostatic Hypotension Market Forecasts and Analysis
10.4.3 Middle East and Africa Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Drug Type
10.4.4 Middle East and Africa Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Non- Pharmacological treatment options
10.4.5 Middle East and Africa Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Neurogenic Orthostatic Hypotension Market
10.4.6.1.1 South Africa Neurogenic Orthostatic Hypotension Market by Drug Type
10.4.6.1.2 South Africa Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.4.6.1.3 South Africa Neurogenic Orthostatic Hypotension Market by End User
10.4.6.2 Saudi Arabia Neurogenic Orthostatic Hypotension Market
10.4.6.2.1 Saudi Arabia Neurogenic Orthostatic Hypotension Market by Drug Type
10.4.6.2.2 Saudi Arabia Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.4.6.2.3 Saudi Arabia Neurogenic Orthostatic Hypotension Market by End User
10.4.6.3 U.A.E Neurogenic Orthostatic Hypotension Market
10.4.6.3.1 U.A.E Neurogenic Orthostatic Hypotension Market by Drug Type
10.4.6.3.2 U.A.E Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.4.6.3.3 U.A.E Neurogenic Orthostatic Hypotension Market by End User
10.4.6.4 Rest of Middle East and Africa Neurogenic Orthostatic Hypotension Market
10.4.6.4.1 Rest of Middle East and Africa Neurogenic Orthostatic Hypotension Market by Drug Type
10.4.6.4.2 Rest of Middle East and Africa Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.4.6.4.3 Rest of Middle East and Africa Neurogenic Orthostatic Hypotension Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Neurogenic Orthostatic Hypotension Market Overview
10.5.2 South and Central America Neurogenic Orthostatic Hypotension Market Forecasts and Analysis
10.5.3 South and Central America Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Drug Type
10.5.4 South and Central America Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Non- Pharmacological treatment options
10.5.5 South and Central America Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By End User
10.5.6 South and Central America Neurogenic Orthostatic Hypotension Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Neurogenic Orthostatic Hypotension Market
10.5.6.1.1 Brazil Neurogenic Orthostatic Hypotension Market by Drug Type
10.5.6.1.2 Brazil Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.5.6.1.3 Brazil Neurogenic Orthostatic Hypotension Market by End User
10.5.6.2 Argentina Neurogenic Orthostatic Hypotension Market
10.5.6.2.1 Argentina Neurogenic Orthostatic Hypotension Market by Drug Type
10.5.6.2.2 Argentina Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.5.6.2.3 Argentina Neurogenic Orthostatic Hypotension Market by End User
10.5.6.3 Rest of South and Central America Neurogenic Orthostatic Hypotension Market
10.5.6.3.1 Rest of South and Central America Neurogenic Orthostatic Hypotension Market by Drug Type
10.5.6.3.2 Rest of South and Central America Neurogenic Orthostatic Hypotension Market by Non- Pharmacological treatment options
10.5.6.3.3 Rest of South and Central America Neurogenic Orthostatic Hypotension Market by End User

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. NEUROGENIC ORTHOSTATIC HYPOTENSION MARKET, KEY COMPANY PROFILES
12.1. AMGEN
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. UPSHER-SMITH LABORATORIES
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MYLAN INC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. CHELSEA THERAPEUTICS
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. APOTEX, INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. F. HOFFMAN-LA ROCHE
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. AMNEAL PHARMACEUTICALS INC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. H. LUNDBECK AS
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. NOVARTIS AG
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. PFIZER, INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Amgen
2. Upsher-Smith Laboratories
3. Mylan Inc
4. Chelsea Therapeutics
5. Apotex, Inc.
6. F. Hoffman-La Roche
7. Amneal Pharmaceuticals Inc
8. H. Lundbeck AS
9. Novartis AG
10. Pfizer, Inc.
TIPRE00018834
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking